Table 1.

Baseline demographic and clinical characteristics of the PD and control participants

Characteristic	PD	Controls	Difference (P Value)
N	43	35
Age (yr)	57.5 ± 8.45	56.23 ± 7.83	0.5
Male Female	35 8	27 8	0.64
H & Y stage	1.91 ± 0.48	n/a
Total MDS‐UPDRSa	45.41 ± 17.22	3.17 ± 2.7	<0.001
MDS‐UPDRS I	6.91 ± 4.71	1.80 ± 2.08	<0.001
MDS‐UPDRS II	9.21 ± 6.10	0.23 ± 0.73	<0.001
MDS‐UPDRS III	27.67 ± 11.22	1.14 ± 1.06	<0.001
MDS‐UPDRS IV	1.63 ± 2.65	0 ± 0	<0.001
MoCA	26.86 ± 2.46	28.34 ± 1.35	0.001
Mean disease duration (yr)	3.51 ± 2.86	n/a
Proportion of patients taking dopaminergic medication	81%	n/a
Experiencing fluctuations (%)b	37% (30% experience at least a slight impact)	n/a
MDS‐UPDRS‐defined TD and PIGD PD subtypes	29 TD; 9 PIGD; 5 indeterminate	n/a
Experiencing dyskinesia (%)c	9.3%	n/a

Data are mean ± SD or proportions.

^aTotal MDS‐UPDRS = MDS‐UPDRS I + MDS‐UPDSR II + MDS‐UPDRS III.

^bProportion of patients with MDS‐UPDRS 4.3 “time spent in the off state >0.”

^cProportion of patients with MDS‐UPDRS 4.1 “time spent with dyskinesia >0.” A total of 1 PD had functional impact of dyskinesias, indicated by MDS‐UPDRS 4.2 > 0.

TD, tremor dominant. n/a, not applicable.